AR and prostate cancer: Additional specific dependencies may be targetable in these tumors; for instance, since DAB2IP levels show strong inverse correlation with AR activation in CRPC [28, 29], DAB2IP-deficient prostate cancers may be particularly sensitive to AR inhibitors.